stock poised for growth amid NASH market potential By Investing.com
Madrigal Pharmaceuticals, Inc. (NASDAQ:), a biopharmaceutical company with a market capitalization of $7.45 billion focused on developing treatments for cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH), has garnered significant attention from investors and analysts alike. According to InvestingPro data, the stock has delivered an impressive 40.83% return over the past year, significantly outperforming broader market indices.
Want deeper insights? InvestingPro offers 11 additional exclusive tips for MDGL, along with comprehensive financial analysis and Fair Value estimates. The company’s flagship drug, Rezdiffra, has positioned Madrigal as a frontrunner in the race to address the growing NASH market. This…
